Chronic myelomonocytic leukemia: JAK2 inhibitor ruxolitinib has promising efficacy
Thursday, May 28, 2015 - 20:50
in Health & Medicine
Scientists are reporting on the first phase 1 study of the JAK2 inhibitor ruxolitinib in CMML patients.